Ypsomed Holding AG · SIX:YPSN
Ypsomed — H1 2020/21 Earnings Presentation
37 slides from Ypsomed's earnings presentation, Nov 3, 2020
Slide 1: 2020/21 Half Year Results
2020/21 Half Year Results Ypsomed Webcast, 03 November 2020
Slide 2: Important information
Important information The information contained in this document has not been verified by an independent source. It should be taken with caution and no assurance or guarantee is given (either explicit or implied) with regard to the fairness, accuracy, completeness or correctness of the information o
Slide 3: Committed to the society
Committed to the society Our future-oriented business model has proven itself – Our products are vital for people with chronic diseases. – Our processes are highly automated and vertically integrated. – Production, supply chains and the supply of customers are ensured. We continue to pursue our
Slide 4: More jobs created during the crisis
We have created 102 more jobs during the crisis, with 88 new jobs in Switzerland 4 | Ypsomed Holding AG | 2020/21 Half Year Results
Slide 5: Strategic initiatives for sustainable objectives
Strategic initiatives for sustainable objectives Expansion Establishment as a global provider Innovation Digitisation of the portfolio Operational Excellence Extending cost leadership Sustainability Responsibility to society, zero carbon emission by 2030 5 | Ypsomed Holding AG | 2020/21 Half
Slide 6: Strategic progress
Strategic progress Expansion Injection Systems: Sales growth of +22% year-on-year YpsoPump®: Finalizing an important U.S. partnership Innovation YpsoPump®: mylife™ Loop Program on track YpsoDose®: already two committed customer orders Operational Excellence YpsoMate®: Doubling capacities
Slide 7: Investments for sustainable growth
Investments for sustainable growth 7 | Ypsomed Holding AG | 2020/21 Half Year Results
Slide 8: Financing for growth ensured
Financing for growth ensured To fund the significant growth investments, the short-term credit line with banks was increased from CHF 210 million to CHF 265 million. The Michel family shareholder group is exercising its commitment and contributing an additional CHF 45 million in the form of a lo
Slide 9: Sale of YpsoPod relieves Ypsomed
Sale of YpsoPod® relieves Ypsomed The development project YpsoPod® Ypsomed participates in a later will be sold to TecMed AG, a success or can buy back the company controlled by Willy Michel, market-ready product. for CHF 13 million as of 01.01.2021. Ypsomed thereby increases the Ypsomed wil
Slide 10: Current environment – Ypsomed Delivery System
Current environment – Ypsomed Delivery System The operating business with deliveries for already approved drugs is performing reliably. For our pharmaceutical partners, the commercial launch of new products is partially limited. The projects continue to run largely uninterrupted, with only a f
Slide 11: Ypsomed Delivery Systems - Platform device strategy
Ypsomed Delivery Systems - Platform device strategy Reduction of risks and shortened "time-to-market". Technological leadership due to consistent ongoing development. Cost leadership due to scaling effects and highly automated production. 11 | Ypsomed Holding AG | 2020/21 Half Year Results
Slide 12: Current environment – Ypsomed Diabetes Care
Current environment – Ypsomed Diabetes Care Consumables such as infusion sets, pen needles and test strips are still needed by our customers. The gaining of new users of the mylife™ YpsoPump® remains severely restricted. We consistently use the time for: – commercial enhancements, – the implem
Slide 13: Current environment – Insulin pump therapy
Current environment – Insulin pump therapy Access to new customers is highly Tenders in Nordics, Poland, Spain dependent on the organisation of the and Italy were postponed. regional health care system. There is a clear pent-up demand. In Germany and Switzerland, many patients are also treat
Slide 14: Outlook for the financial year 2020/21
Outlook for the financial year 2020/21 Based on our well-diversified business model, we expect for the 2020/21 financial year a slight increase in sales and still further growth in operating profit from core operating activities compared to previous year, despite the pandemic. Strict cost contro
Slide 15: Diversified portfolio delivers +4.6% growth in sales
Diversified portfolio delivers +4.6 % growth in sales * In 2018/19 only contributions from continuing operations. For information about discontinued operations, see Annual Report 2019/20, page 59. 15 | Ypsomed Holding AG | 2020/21 Half Year Results
Slide 16: YDS is the strongest revenue driver
YDS is the strongest revenue driver Sales in Ypsomed Delivery Systems (YDS) segment rose by 18.9 % to CHF 108.3 million. In Ypsomed Diabetes Care (YDC) segment, turnover declined by -8.9 % to CHF 83.9 million. Revenues in the Others segment decreased slightly by -4.3 % to CHF 7.1 million. 16 |
Slide 17: Development of sales Ypsomed Delivery Systems
Development of sales Ypsomed Delivery Systems Growth of +59 % in two years Sales increase of +21.7 % for Injection Systems year-on-year. Next to autoinjectors, UnoPen™, FixPen™ und reusable pens contribute to the growth. Project revenues have also increased compared to previous year. The sal
Slide 18: Development of sales Ypsomed Diabetes Care
Development of sales Ypsomed Diabetes Care Due to COVID-19, the sales contribution of mylife™ YpsoPump® decline by -13.7 % compared to previous year. Pen needles sales are down -12.3 % due to loss of a mayor customer in the USA and stockpiling in March 2020. Revenues of test strips fell -9.1 %
Slide 19: EBIT development solid
EBIT development solid Growth and efficiency improvements 19 | Ypsomed Holding AG | 2020/21 Half Year Results
Slide 20: Ypsomed Delivery Systems
Ypsomed Delivery Systems Pen systems Autoinjector Patch injector Smart services systems systems 20 | Ypsomed Holding AG | 2020/21 Half Year Results
Slide 21: YpsoMate Zero – first zero carbon emission autoinjector
YpsoMate® Zero – first zero carbon emission autoinjector Pioneering development based on the established YpsoMate® platform. Comprehensive life-cycle assessment. Use of alternative bio-polymers for product and packaging. Optimisation along the entire supply chain according to the principle o
Slide 22: YpsoMate Zero – the three areas of impact
YpsoMate® Zero – the three areas of impact 22 | Ypsomed Holding AG | 2020/21 Half Year Results
Slide 23: Doubling the capacities for YpsoMate
Doubling the capacities for YpsoMate® YpsoMate® 1.0 Installation of a third automated assembly line and additional, complete injection moulding set-ups in Schwerin. Increase of the existing injection moulding capacities in Burgdorf. YpsoMate® 2.25 Installation of a second automated assembly li
Slide 24: Increase in order pipeline very strong
Increase in order pipeline very strong The acquisition of customer orders is even accelerating in the current environment. In the last 6 months we have already been able to ensure as many projects as in the entire previous business year. This includes two initial customer orders for our new pa
Slide 25: Ypsomed Diabetes Care
Ypsomed Diabetes Care Pen needles Blood glucose Infusion systems Therapy monitoring management 25 | Ypsomed Holding AG | 2020/21 Half Year Results
Slide 26: mylife YpsoPump – Update market entry USA
mylife™ YpsoPump® – Update market entry USA We will submit to the American FDA for approval in a step-by-step process following the interoperable ACE insulin pump approval pathway with the Dexcom CGM connectivity. First the insulin pump YpsoPump® stand-alone as an interim step, subsequently the
Slide 27: mylife YpsoPump – Update outside the USA
mylife™ YpsoPump® – Update outside the USA Outside the USA, we continue to implement our mylife™ Loop Program. 27 | Ypsomed Holding AG | 2020/21 Half Year Results
Slide 28: mylife YpsoPump – mylife Loop Program on track
mylife™ YpsoPump® – mylife™ Loop Program on track mylife™ Assist Wireless connectivity: all data, including CGM, at a glance on the smartphone and in the cloud. mylife™ Dose Bolus calculation and delivery from your smartphone. Via a secure Bluetooth connection to mylife™ YpsoPump® by the user.
Slide 29: mylife YpsoPump – mylife Assist feature
mylife™ YpsoPump® – mylife™ Assist1) feature App-based Dexcom G6 CGM integration 1) Product mylife Assist not approved and not commercially available. Features and performance of any future technologies may vary. The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, In
Slide 30: mylife YpsoPump – assembly line for infusion set
mylife™ YpsoPump® – assembly line for infusion set Fully automated production line for the new generation of the YpsoPump® Orbit® infusion set 2.0. The installation takes place in a clean room in Schwerin. Full automation ensures supply for increasing demand and creates qualified jobs. Produ
Slide 31: mylife YpsoPump – Explorer App
mylife™ YpsoPump® – Explorer App Introduction of a digital training tool 31 | Ypsomed Holding AG | 2020/21 Half Year Results
Slide 32: Establishing a digital hub in Barcelona
Establishing a digital hub in Barcelona We are significantly expanding our internal resources for the consistent implementation of digitisation. For this, we are setting up a digital hub in Barcelona. The set-up is proceeding successfully and we have already been able to recruit 15 new employe
Slide 33: Our Sustainability Program
Our Sustainability Program 33 | Ypsomed Holding AG | 2020/21 Half Year Results
Slide 34: Sustainable logistics by replacement of pallets by silos
Sustainable logistics by replacement of pallets by silos Through storage in silos we save large quantities of packaging material for the granulate, per year at the Solothurn- site only: – 10’800 kg wooden pallets – 8’784 kg carton packaging – 1’008 kg plastic film – 288 kg metal We gain addition
Slide 35: Lasting effects of COVID-19
Lasting effects of COVID-19 Home Care The global relevance of our vision of selfcare is increasing. Digitisation We see a significant acceleration of digitisation in the healthcare sector. Affordability The demand for affordable medical devices is growing. Supply Chain Supply chain reliabili
Slide 36: Ypsomed makes selfcare simpler
Ypsomed makes selfcare simpler Diabetes Care – Established diabetes specialist with 35 years’ experience Pen needles Blood glucose Infusion Therapy monitoring systems management Delivery Systems – Preferred partner for systems to administer liquid drugs Pen systems Autoinjector Patch injector Smart
Slide 37: Slide 37